期刊
CANCERS
卷 11, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/cancers11122010
关键词
KRAS; tumor microenvironment; cancer therapy; immunotherapy; lung cancer; pancreatic cancer; colorectal cancer
类别
资金
- FEDER funds through the Operational Programme for Competitiveness Factors (COMPETE 2020)
- Programa Operacional de Competitividade e Internacionalizacao (POCI)
- Programa Operacional Regional do Norte (Norte 2020)
- European Regional Development Fund (ERDF)
- National Funds through Portuguese Foundation for Science and Technology (FCT) [PTDC/MED-ONC/31354/2017]
- Portuguese Foundation for Science and Technology (FCT) [SFRH/BD/131156/2017]
- [NORTE-01-0145-FEDER-000029]
- [NORTE-01-0145-FEDER-000012]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/131156/2017, PTDC/MED-ONC/31354/2017] Funding Source: FCT
Current evidence strongly suggests that cancer cells depend on the microenvironment in order to thrive. In fact, signals from the surrounding tumor microenvironment are crucial for cancer cells ' aggressiveness, altering their expression profile and favoring their metastatic potential. As such, targeting the tumor microenvironment to impair cancer progression became an attractive therapeutic option. Interestingly, it has been shown that oncogenic KRAS signaling promotes a pro-tumorigenic microenvironment, and the associated crosstalk alters the expression profile of cancer cells. These findings award KRAS a key role in controlling the interactions between cancer cells and the microenvironment, granting cancer a poor prognosis. Given the lack of effective approaches to target KRAS itself or its downstream effectors in the clinic, exploring such interactions may open new perspectives on possible therapeutic strategies to hinder mutant KRAS tumors. This review highlights those communications and their implications for the development of effective therapies or to provide insights regarding response to existing regimens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据